International Stem Cell CORP financial data

Symbol
ISCO on OTC
Industry
Pharmaceutical Preparations
Location
9745 Businesspark Avenue, San Diego, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
BTHC III INC. (to 1/19/2007)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 74.8 % +11.9%
Quick Ratio 27 % -5.66%
Debt-to-equity -129 % -4.75%
Return On Equity 16.8 %
Return On Assets -12.4 % -580%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8M shares 0%
Common Stock, Shares, Outstanding 8M shares 0%
Entity Public Float 481K USD -68.6%
Common Stock, Value, Issued 8K USD 0%
Weighted Average Number of Shares Outstanding, Basic 8M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 8M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 8.32M USD +3.25%
Cost of Revenue 3.44M USD +2.41%
Research and Development Expense 581K USD +25.8%
Selling and Marketing Expense 1.26M USD +1.04%
General and Administrative Expense 3.59M USD +6.47%
Costs and Expenses 8.87M USD +5.11%
Operating Income (Loss) -550K USD -44.4%
Nonoperating Income (Expense) -134K USD -126%
Net Income (Loss) Attributable to Parent -684K USD -596%
Earnings Per Share, Basic -0.07 USD/shares -600%
Earnings Per Share, Diluted -0.07 USD/shares -600%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current 810K USD +22.4%
Inventory, Net 1.42M USD +9.18%
Other Assets, Current 11K USD -65.6%
Assets, Current 3.82M USD +3.66%
Property, Plant and Equipment, Net 286K USD +11.7%
Operating Lease, Right-of-Use Asset 460K USD -28.8%
Intangible Assets, Net (Excluding Goodwill) 758K USD -9.44%
Assets 5.59M USD -3.32%
Accounts Payable, Current 377K USD +13.9%
Accrued Liabilities, Current 572K USD +9.79%
Liabilities, Current 5.02M USD +5.9%
Operating Lease, Liability, Noncurrent 286K USD -51.4%
Liabilities 5.31M USD -0.41%
Retained Earnings (Accumulated Deficit) -111M USD -0.62%
Stockholders' Equity Attributable to Parent -4.02M USD -4.42%
Liabilities and Equity 5.59M USD -3.32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -193K USD -189%
Net Cash Provided by (Used in) Financing Activities 250K USD -69.7%
Net Cash Provided by (Used in) Investing Activities -9K USD +40%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 8M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -202K USD -200%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.29M USD -6.66%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3K USD 0%
Deferred Tax Assets, Valuation Allowance 7.86M USD -65.7%
Deferred Tax Assets, Gross 8.02M USD -65.4%
Operating Lease, Liability 588K USD -30%
Payments to Acquire Property, Plant, and Equipment 8K USD -46.7%
Lessee, Operating Lease, Liability, to be Paid 654K USD -34.5%
Property, Plant and Equipment, Gross 2.67M USD +5.46%
Operating Lease, Liability, Current 302K USD +19.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 119K USD -66.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 360K USD +2.86%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 66K USD -58.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 119K USD -66.9%
Deferred Tax Assets, Operating Loss Carryforwards 5.48M USD -71.6%
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 478K USD -49.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 118K USD -67.2%
Additional Paid in Capital 107M USD +0.49%
Amortization of Intangible Assets 83K USD 0%
Depreciation, Depletion and Amortization 49K USD -3.92%
Deferred Tax Assets, Net of Valuation Allowance 157K USD -26.3%
Share-based Payment Arrangement, Expense 514K USD +18.4%
Interest Expense 139K USD 0%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%